KR100403336B1 - 시클린 의존 키나아제 2 및 ＩκＢ-α의 푸린 억제제 - Google Patents

시클린 의존 키나아제 2 및 ＩκＢ-α의 푸린 억제제 Download PDF

Info

Publication number
KR100403336B1
KR100403336B1 KR10-1999-7000900A KR19997000900A KR100403336B1 KR 100403336 B1 KR100403336 B1 KR 100403336B1 KR 19997000900 A KR19997000900 A KR 19997000900A KR 100403336 B1 KR100403336 B1 KR 100403336B1
Authority
KR
South Korea
Prior art keywords
delete delete
amino
alkyl
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7000900A
Other languages
English (en)
Korean (ko)
Other versions
KR20000029781A (ko
Inventor
로버트 티. 럼
췌리 린 블럼
리챠드 매크만
마이클 엠. 위크
스티븐 알. 스코우
Original Assignee
씨브이 쎄러퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨브이 쎄러퓨틱스, 인코포레이티드 filed Critical 씨브이 쎄러퓨틱스, 인코포레이티드
Publication of KR20000029781A publication Critical patent/KR20000029781A/ko
Application granted granted Critical
Publication of KR100403336B1 publication Critical patent/KR100403336B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-1999-7000900A 1996-08-02 1997-08-01 시클린 의존 키나아제 2 및 ＩκＢ-α의 푸린 억제제 Expired - Fee Related KR100403336B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/692,012 1996-08-02
US08/692,012 US5866702A (en) 1996-08-02 1996-08-02 Purine inhibitors of cyclin dependent kinase 2
US8/692,012 1996-08-02

Publications (2)

Publication Number Publication Date
KR20000029781A KR20000029781A (ko) 2000-05-25
KR100403336B1 true KR100403336B1 (ko) 2003-10-30

Family

ID=24778922

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7000900A Expired - Fee Related KR100403336B1 (ko) 1996-08-02 1997-08-01 시클린 의존 키나아제 2 및 ＩκＢ-α의 푸린 억제제

Country Status (25)

Country Link
US (1) US5866702A (enExample)
EP (1) EP1021186B1 (enExample)
JP (1) JP2000515550A (enExample)
KR (1) KR100403336B1 (enExample)
CN (1) CN1161356C (enExample)
AT (1) ATE298572T1 (enExample)
AU (1) AU731778B2 (enExample)
BR (1) BR9710801A (enExample)
CA (1) CA2262454C (enExample)
CZ (1) CZ299381B6 (enExample)
DE (1) DE69733674T2 (enExample)
DK (1) DK1021186T3 (enExample)
ES (1) ES2242981T3 (enExample)
GE (1) GEP20022786B (enExample)
HU (1) HUP9902414A3 (enExample)
IL (1) IL128323A (enExample)
NO (1) NO323775B1 (enExample)
NZ (1) NZ334061A (enExample)
PL (1) PL189775B1 (enExample)
PT (1) PT1021186E (enExample)
RU (1) RU2220968C2 (enExample)
SI (1) SI1021186T1 (enExample)
TR (1) TR199900683T2 (enExample)
UA (1) UA71890C2 (enExample)
WO (1) WO1998005335A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7296896A (en) * 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
ES2253821T3 (es) * 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
JP2001516694A (ja) 1997-08-07 2001-10-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
AU1926899A (en) 1997-12-19 1999-07-12 Affymetrix, Inc. Exploiting genomics in the search for new drugs
EP1418244A1 (en) * 1997-12-19 2004-05-12 Affymetrix, Inc. Exploiting genomics in the search for new drugs
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
AU753015B2 (en) 1998-03-04 2002-10-03 Cyclacel Limited Cyclin dependent kinase inhibitor
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
ATE318818T1 (de) * 1998-06-16 2006-03-15 Us Gov Health & Human Serv Annellierte azepinone als inhibitoren cyclin- abhängiger kinasen
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
KR100377138B1 (ko) * 1998-11-10 2003-06-12 주식회사 엘지생명과학 퓨린구조를갖는싸이클린의존키나아제저해제,그제조방법및그를함유하는항암제조성물
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU2004200192B2 (en) * 1999-02-01 2006-11-16 Gilead Palo Alto, Inc. Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
MXPA01007851A (es) * 1999-02-01 2003-06-04 Cv Therapeutics Inc Inhibidores purina de cinasa 2 e 1kb-alfa dependientes del ciclin.
KR20000055080A (ko) * 1999-02-03 2000-09-05 성재갑 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
SI1194425T1 (sl) * 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2001044257A1 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
EP1244668B1 (en) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
KR20010077073A (ko) * 2000-01-31 2001-08-17 박호군 Ｃ-２,６,９ 위치에 치환된 이소프로필퓨린 유도체 및그의 제조 방법
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
AU2509602A (en) * 2000-12-20 2002-07-01 Sod Conseils Rech Applic Cyclin-dependent kinase (CDK) and glycolene synthase kinase-3 (GSK-3) inhibitors
FR2818278B1 (fr) * 2000-12-20 2003-02-28 Sod Conseils Rech Applic Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US6667311B2 (en) 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
EP1764118B1 (en) 2002-02-15 2010-08-25 Gilead Palo Alto, Inc. Polymer coating for medical devices
CN1305850C (zh) 2002-03-13 2007-03-21 詹森药业有限公司 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
US7273864B2 (en) * 2002-10-15 2007-09-25 The Scripps Research Institute Compositions and methods for inducing osteogenesis
JP5064795B2 (ja) 2003-04-07 2012-10-31 アジェニックス ユーエスエー インク． サイクリン依存性キナーゼの阻害剤、組成物及びそれに関連する使用
CN100447143C (zh) * 2003-08-15 2008-12-31 Irm责任有限公司 作为rtk抑制剂的6-取代的苯胺基嘌呤
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
KR20060121878A (ko) * 2003-09-25 2006-11-29 얀센 파마슈티카 엔.브이. Ｈｉｖ를 저해하는 퓨린 유도체
KR101155883B1 (ko) 2003-12-23 2012-06-20 아제닉스 유에스에이 인코포레이티드 사이클린 의존적 키나제 저해제, 그 조성물 및 그의 용도
JP2006056879A (ja) * 2004-07-21 2006-03-02 Kobe Univ インスリン抵抗性の改善剤、及びそのスクリーニング方法
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US20080125404A1 (en) * 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
GB0419175D0 (en) * 2004-08-27 2004-09-29 Cyclacel Ltd Method of treatment and compositions
CN101899049A (zh) 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
WO2006051951A1 (ja) * 2004-11-12 2006-05-18 Kazuhito Tomizawa Cdk5阻害剤を含む糖尿病治療薬
KR100677396B1 (ko) * 2004-11-20 2007-02-02 엘지전자 주식회사 음성인식장치의 음성구간 검출방법
ES2308731T3 (es) * 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
US8080555B2 (en) * 2005-05-16 2011-12-20 Prometic Biosciences Inc. Purine derivatives and their use for treatment of autoimmune diseases
EP1940843A4 (en) * 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
WO2007062288A2 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007209689B2 (en) 2006-01-27 2012-03-15 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
GB0606283D0 (en) * 2006-03-29 2006-05-10 Cyclacel Ltd Process
WO2008106128A2 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2008138232A1 (en) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
ATE554078T1 (de) * 2007-07-26 2012-05-15 Vitae Pharmaceuticals Inc Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
FR2920776B1 (fr) * 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
CA2703138A1 (en) * 2007-10-26 2009-04-30 F. Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
EP2229368A1 (en) 2007-12-11 2010-09-22 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (en) * 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2714532A1 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
JP5730021B2 (ja) * 2008-02-15 2015-06-03 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
WO2009117109A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134392A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ588954A (en) 2008-05-01 2012-08-31 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5451752B2 (ja) * 2008-05-01 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
US8158624B2 (en) * 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
PL2324018T3 (pl) 2008-07-25 2014-02-28 Boehringer Ingelheim Int Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
CA2752150A1 (en) 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
MX2011010332A (es) * 2009-04-03 2011-11-29 S Bio Pte Ltd Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CN103003279B (zh) 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
US8969556B2 (en) * 2010-10-12 2015-03-03 Case Western Reserve University Purine-based triazoles
KR20130137628A (ko) 2010-11-02 2013-12-17 베링거 인겔하임 인터내셔날 게엠베하 대사 장애를 치료하기 위한 약제학적 병용물
EP3053925A1 (en) 2010-12-16 2016-08-10 F. Hoffmann-La Roche AG Tricyclic pi3k inhibitor compounds and methods of use
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
CN103814030A (zh) * 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2664619B1 (en) * 2012-05-16 2017-07-12 Manros Therapeutics Purine derivatives as tools for screening anti-Alzheimer compounds
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CN104086551B (zh) * 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN117736209A (zh) 2015-02-27 2024-03-22 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US20250101023A1 (en) * 2022-01-21 2025-03-27 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Heteroaryl derivative and uses thereof
CN117659016A (zh) * 2022-08-26 2024-03-08 嘉兴优博生物技术有限公司 细胞周期蛋白调节剂
IL321433A (en) 2022-12-16 2025-08-01 Astrazeneca Ab Purines 2,6,9 trimethylated
CN116813621A (zh) * 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028353A (en) * 1971-07-29 1977-06-07 Polaroid Corporation Novel chemical compounds
US4028358A (en) * 1973-09-04 1977-06-07 Liotta Charles L 6-Fluoro-9-perfluorobutyl purine
US4405781A (en) * 1981-03-02 1983-09-20 Polaroid Corporation Method for preparing salts of 6-chloropurine
NO169901C (no) * 1985-04-19 1992-08-19 Sankyo Co Analogifremgangsmaate for fremstilling av griseolsyrederivater
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
FR2699176B1 (fr) * 1992-12-11 1995-03-03 Adir Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
AU7296896A (en) * 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
WO1997018212A1 (en) * 1995-11-14 1997-05-22 Pharmacia & Upjohn S.P.A. Aryl and heteroaryl purine compounds
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법

Also Published As

Publication number Publication date
GEP20022786B (en) 2002-09-25
ATE298572T1 (de) 2005-07-15
CA2262454C (en) 2006-02-07
DE69733674T2 (de) 2006-05-04
CN1231611A (zh) 1999-10-13
US5866702A (en) 1999-02-02
AU3900097A (en) 1998-02-25
AU731778B2 (en) 2001-04-05
KR20000029781A (ko) 2000-05-25
PT1021186E (pt) 2005-11-30
BR9710801A (pt) 2001-11-27
JP2000515550A (ja) 2000-11-21
EP1021186A4 (en) 2000-07-26
CN1161356C (zh) 2004-08-11
TR199900683T2 (xx) 2002-01-21
CZ299381B6 (cs) 2008-07-09
NO990466D0 (no) 1999-02-01
WO1998005335A1 (en) 1998-02-12
PL331408A1 (en) 1999-07-19
RU2220968C2 (ru) 2004-01-10
ES2242981T3 (es) 2005-11-16
IL128323A0 (en) 2000-01-31
CA2262454A1 (en) 1998-02-12
SI1021186T1 (sl) 2005-12-31
PL189775B1 (pl) 2005-09-30
EP1021186B1 (en) 2005-06-29
NO323775B1 (no) 2007-07-02
EP1021186A1 (en) 2000-07-26
DK1021186T3 (da) 2005-10-17
HUP9902414A2 (hu) 2001-04-28
NZ334061A (en) 2000-08-25
IL128323A (en) 2001-11-25
HUP9902414A3 (en) 2002-04-29
DE69733674D1 (de) 2005-08-04
HK1020884A1 (en) 2000-05-26
UA71890C2 (en) 2005-01-17
NO990466L (no) 1999-03-25
CZ33899A3 (cs) 2000-03-15

Similar Documents

Publication Publication Date Title
KR100403336B1 (ko) 시클린 의존 키나아제 2 및 ＩκＢ-α의 푸린 억제제
JP3681984B2 (ja) サイクリン依存キナーゼ２およびＩκＢ−αのプリン阻害剤
US6794390B2 (en) Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
WO1998005335A9 (en) PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a)
US9533990B2 (en) Inhibitors of secretion of hepatitis B virus antigens
US6255485B1 (en) Purine inhibitors of protein kinases, G proteins and polymerases
JP2000501408A (ja) 特に抗増殖性を有する新規プリン誘導体およびそれらの生物学的用途
WO2008090181A1 (en) Purine derivatives
US20020035252A1 (en) Purine inhibitors of cyclin dependent kinase 2 & IkBa
Zhao et al. A systematic review on active sites and functions of PIM-1 protein
EP3475286B1 (en) Substituted pyrrolo [2, 3-d]pyridazin-4-ones and pyrazolo [3, 4-d]pyridazin-4-ones as protein kinase inhibitors
AU2004200192B2 (en) Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
US20250084089A1 (en) Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas
JPH07508531A (ja) 治療用ヌクレオシド
MXPA99001176A (en) PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I&kgr;B-&agr;

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20091013

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20101016

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20101016